Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT

Inclusion criteria

• ✓. Provision of signed and dated informed consent form prior to receiving any non-standard of care, protocol-specific procedures.
• ✓. Stated willingness to comply with all study procedures including completion of questionnaires and follow-up visits and availability for the duration of the study.
• ✓. Male or female, aged 18 to 89 years.
• ✓. For females of reproductive potential: use of highly effective contraception (abstinence is acceptable) for at least 1 month prior to study treatment (unless they had given birth within the 1 month prior to study treatment), and agreement to use such a method for at least 30 days after study treatment.
• ✓. Onset of acute DVT symptoms of 14 days or less prior to initial intervention in the study limb.
• ✓. Ability to take oral medication and be willing to adhere to the prescribed anti-coagulant regimen.
• ✓. Post-procedural prescription for at least 28 days low molecular weight heparin followed by therapeutic anticoagulant of investigator's choice for 12 months minimum as part of post-interventional medication regimen.
• ✓. Minimum of 28 days of prescribed antiplatelet agent (aspirin or P2Y12 inhibitor) for patients receiving stents.

Exclusion criteria